Novel Clinical Trial Endpoints in Argentina

Clinical Trials in: Mexico, Argentina, Colombia and Brazil.

Locally-Based, Full Service CRO

Contact us today to learn more.

+ 0
Sites Throughout LATAM
+ 200
Patients in our network
+ 0
Conducted Studies
0 %
Lost-to-Follow Up rate
As a leading CRO in LATAM, we specialize in supporting clinical trials throughout the region. Our extensive experience and broad network of clinical sites enable us to execute trials with speed and efficiency, ensuring high patient recruitment and retention rates.

Novel Clinical Trial Endpoints in Argentina

Novel Clinical Trial Endpoints in Argentina – Full Service CRO

Clinical trials play a crucial role in advancing medical research and improving patient care. In Brazil, the landscape of clinical trial endpoints is witnessing exciting developments, with an increasing emphasis on novel and innovative measures to assess the safety and efficacy of new treatments.

This blog explores the recent advancements in clinical trial endpoints in Brazil, highlighting how these breakthroughs are revolutionizing the field and contributing to the overall goal of enhancing healthcare outcomes.

Patient-Reported Outcomes (PROs)


The incorporation of patient perspectives in clinical trial endpoints has gained significant recognition in recent years. Patient-reported outcomes (PROs) have become integral to clinical trials conducted in Brazil. PROs provide valuable insights into the impact of treatments on patients’ daily lives, symptom management, and overall quality of life.


By integrating PROs as clinical trial endpoints, researchers gain a deeper understanding of patients’ experiences, preferences, and treatment outcomes, ultimately leading to more patient-centered care.


Biomarkers and Molecular Endpoints


Brazil’s advancements in molecular biology and precision medicine have opened doors to the integration of biomarkers and molecular endpoints in clinical trials. Biomarkers, such as genetic mutations, protein expression, or metabolic activity, serve as objective measurements to assess treatment responses, disease progression, and drug safety.


By leveraging biomarkers and molecular endpoints, researchers in Brazil are at the forefront of personalized medicine, enabling targeted therapies and optimizing healthcare outcomes for specific patient subgroups.


Real-World Data and Observational Endpoints


The utilization of real-world data (RWD) and observational endpoints is another significant development in clinical trials in Brazil. RWD, derived from electronic health records, patient registries, and claims databases, offers a comprehensive view of treatment outcomes in real-world clinical practice.


Observational endpoints allow researchers to examine the long-term safety and effectiveness of treatments in diverse patient populations, complementing traditional randomized controlled trials (RCTs).

By incorporating RWD and observational endpoints, clinical trials in Brazil generate valuable evidence that reflects the complexities of patient care, leading to more informed decision-making and improved healthcare delivery.

Novel Clinical Trial Endpoints in Argentina

Novel Clinical Trial Endpoints in Argentina

Novel Clinical Trial Endpoints in Argentina

Digital Health Technologies and Remote Monitoring

Brazil has embraced the rapid evolution of digital health technologies, including wearable devices, mobile applications, and telemedicine platforms. These technologies have transformed clinical trials by enabling remote patient monitoring, data collection, and enhanced patient engagement.

Digital health endpoints, such as data captured from wearable devices or patient-reported symptoms via mobile apps, provide real-time and continuous measurements, offering a comprehensive understanding of treatment effectiveness and patient experiences. The integration of digital health technologies in clinical trials enhances convenience, reduces patient burden, and improves data quality and trial efficiency.


The evolving landscape of clinical trial endpoints in Brazil is driving the advancement of medical research and patient care. The incorporation of patient-reported outcomes (PROs), biomarkers, molecular endpoints, real-world data (RWD), observational endpoints, and digital health technologies is revolutionizing clinical trials, enabling more personalized and precise interventions.

By embracing these innovative endpoints, researchers in Brazil are shaping the future of medical advancements, facilitating better treatment decisions, improving patient experiences, and ultimately contributing to the overall goal of enhancing healthcare outcomes.

To ensure the successful implementation of novel clinical trial endpoints in Brazil, collaborative efforts between researchers, clinicians, regulatory bodies, and patients are crucial. Standardized methodologies, rigorous validation, and the establishment of guidelines and frameworks are necessary to ensure the reliability and comparability of these endpoints across studies.

With a strong commitment to innovation and collaboration, Brazil’s clinical trials ecosystem has the potential to become a global leader in medical research, attracting partnerships and investments that will benefit patients both within the country and worldwide.

Novel Clinical Trial Endpoints in Argentina

Source: World Courier

Welcome to Cohortias!

of Latin America

Simplify Your Clinical Trials with Our Expert Infrastructure in Latin America

Say goodbye to the complex, costly, and disorganized process of conducting clinical trials. Our infrastructure in Latin America streamlines the launch of studies and ensures adherence to international standards. Schedule a call with us today to discover the path to simplified clinical research in Latin America.

Novel Clinical Trial Endpoints in Argentina

Explore What We Are Doing Better

We define ourselves as a unique team, capable of blending our academic background with a global business mindset to bring the highest standard of quality and operational excellence into clinical research in Latin America.

Early Phase Trials

- First-in-Human Studies.
- Get to patients faster, no IND necessary.
- Valid data for FDA submission.

Rescue Studies

- Regain lost time and boost patient recruitment.
- We work alongside Global CROs to get studies back on track.
- More than 200 sites available.

Phase II & III Trials

- Full-Service Clinical Outsourcing.
- Proven infrastructure that can handle any trial.
- Local Regulatory Experts
- Wide network of sites and physicians.

Medical Devices

- A fast-track platform that will meet your timeline.
- We take care of everything, from shipping requirements all the way to data collection.
Novel Clinical Trial Endpoints in Argentina

Full Service CRO in LATAM

Outsourcing Clinical Trials to Latin America

Unlock the advantages and opportunities of outsourcing clinical trials to Latin America. Diverse patient population, streamlined regulations, and cost-effectiveness

Lower Operating Costs

From lower labor costs to lower costs for rent, utilities, and equipment, you can save money on your clinical trial budget while still ensuring the quality of your trial

Access to Emerging Markets

Latin America offers access to emerging markets, providing an opportunity for pharmaceutical companies to expand their reach and reach new patient populations.

Novel Clinical Trial Endpoints in Argentina

Cohortias is redefining Clinical Research in Latin America

We are committed to become leaders in providing clinical research services in Latin America. Here at Cohortias, we combine our academic roots, proven experience and a large pool of patients from an extensive network of sites.

Our main purpose is to deliver high quality data.

Novel Clinical Trial Endpoints in Argentina

Clinical Research in Latin America

Cohortias has built an extensive and highly reputable network of clinical sites which can access patients in a timely manner and operate within a standard-of-care comparable to the U.S. healthcare system.


  • Site Management

  • Data Management

  • Site Selection

  • Regulatory Submissions

  • Clinical Monitoring

  • Protocol Development


Beta Trials Platform

  • First-in-human studies

Medical Devices

  • Pilot and Pivotal Device Studies

Phases I – III

  • We partner with our clients to bring their products in a fast and efficient manner to the market with the highest quality standards


  • Diabetes/Metabolic Syndromes
  • Infectious Diseases
  • Cardiovascular
  • Neurology
  • Respiratory
  • Oncology

Novel Clinical Trial Endpoints in Argentina

Clinical Research in Latin America

Academic Leadership and Extensive Clinical Site Network for Efficient Clinical Trials

  • Our peer-to-peer management approach guarantees high patient recruitment and retention in any clinical trial

High Speed Execution

  • We offer the quickest start-up times in each country.
  • Efficient Clinical Site Selection and Contracting.
  • Benefit from our extensive network of clinical sites and streamlined contracting process.

Operational Excellence

  • Proven record of delivering rescue studies, we consistently exceed industry performance standards.
  • Our team provides efficient query resolution to keep your trial on track.

Business Insight and Flexibility

  • We offer innovative pricing models and short lines of communication to ensure maximum flexibility and cost-effectiveness.
  • At Cohortias, we prioritize  short lines of communication to ensure efficient collaboration.
  • Swift adaptation to changes in the trial landscape to keep your study on schedule.

Novel Clinical Trial Endpoints in Argentina

We provide our services with offices in:

Colombia &

Daniela Maresca
Daniela Maresca | Country Lead Argentina
Martín Hernández-Torre | CMO
Maritza Rojas | CRA II
Pedro Alvarez | Business Development Manager
Samantha Rodriguez Cohortias
Samantha Rdz. | Start-Up Manager
Novel Clinical Trial Endpoints in Argentina

The Cohortias Team

Novel Clinical Trial Endpoints in Argentina

As the largest South American Contract research Organization, we know the Advantages and Challenges Of the Region

Let Us Guide You Through The Latin American Clinical Research Landscape

Novel Clinical Trial Endpoints in Argentina

Network & Partnerships